These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 9151681)
21. Functional analysis of the cellular receptor for urokinase in plasminogen activation. Receptor binding has no influence on the zymogenic nature of pro-urokinase. Ellis V J Biol Chem; 1996 Jun; 271(25):14779-84. PubMed ID: 8662951 [TBL] [Abstract][Full Text] [Related]
22. Ligand binding regions in the receptor for urokinase-type plasminogen activator. Liang OD; Chavakis T; Kanse SM; Preissner KT J Biol Chem; 2001 Aug; 276(31):28946-53. PubMed ID: 11501527 [TBL] [Abstract][Full Text] [Related]
23. Autocrine saturation of pro-urokinase receptors on human A431 cells. Stoppelli MP; Tacchetti C; Cubellis MV; Corti A; Hearing VJ; Cassani G; Appella E; Blasi F Cell; 1986 Jun; 45(5):675-84. PubMed ID: 3011276 [TBL] [Abstract][Full Text] [Related]
24. Urokinase induces basophil chemotaxis through a urokinase receptor epitope that is an endogenous ligand for formyl peptide receptor-like 1 and -like 2. de Paulis A; Montuori N; Prevete N; Fiorentino I; Rossi FW; Visconte V; Rossi G; Marone G; Ragno P J Immunol; 2004 Nov; 173(9):5739-48. PubMed ID: 15494526 [TBL] [Abstract][Full Text] [Related]
25. Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner. Nguyen DH; Catling AD; Webb DJ; Sankovic M; Walker LA; Somlyo AV; Weber MJ; Gonias SL J Cell Biol; 1999 Jul; 146(1):149-64. PubMed ID: 10402467 [TBL] [Abstract][Full Text] [Related]
26. Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides. Bürgle M; Koppitz M; Riemer C; Kessler H; König B; Weidle UH; Kellermann J; Lottspeich F; Graeff H; Schmitt M; Goretzki L; Reuning U; Wilhelm O; Magdolen V Biol Chem; 1997; 378(3-4):231-7. PubMed ID: 9165076 [TBL] [Abstract][Full Text] [Related]
27. Serine phosphorylation of biosynthetic pro-urokinase from human tumor cells. Mastronicola MR; Stoppelli MP; Migliaccio A; Auricchio F; Blasi F FEBS Lett; 1990 Jun; 266(1-2):109-14. PubMed ID: 2114315 [TBL] [Abstract][Full Text] [Related]
28. Mechanisms of pertussis toxin-induced myelomonocytic cell adhesion: role of Mac-1(CD11b/CD18) and urokinase receptor (CD87). Wong WS; Simon DI; Rosoff PM; Rao NK; Chapman HA Immunology; 1996 May; 88(1):90-7. PubMed ID: 8707356 [TBL] [Abstract][Full Text] [Related]
31. The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation. Behrendt N; List K; Andreasen PA; Danø K Biochem J; 2003 Apr; 371(Pt 2):277-87. PubMed ID: 12534347 [TBL] [Abstract][Full Text] [Related]
32. The chemotactic action of urokinase on smooth muscle cells is dependent on its kringle domain. Characterization of interactions and contribution to chemotaxis. Mukhina S; Stepanova V; Traktouev D; Poliakov A; Beabealashvilly R; Gursky Y; Minashkin M; Shevelev A; Tkachuk V J Biol Chem; 2000 Jun; 275(22):16450-8. PubMed ID: 10749881 [TBL] [Abstract][Full Text] [Related]
33. Sequences within domain II of the urokinase receptor critical for differential ligand recognition. Li Y; Lawrence DA; Zhang L J Biol Chem; 2003 Aug; 278(32):29925-32. PubMed ID: 12761227 [TBL] [Abstract][Full Text] [Related]
34. Cytokines induce urokinase-dependent adhesion of human myeloid cells. A regulatory role for plasminogen activator inhibitors. Waltz DA; Sailor LZ; Chapman HA J Clin Invest; 1993 Apr; 91(4):1541-52. PubMed ID: 8386190 [TBL] [Abstract][Full Text] [Related]
35. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87). Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401 [TBL] [Abstract][Full Text] [Related]
36. Regulation of the uPAR/uPA system expressed on monocytes by the deactivating cytokines, IL-4, IL-10 and IL-13: consequences on cell adhesion to vitronectin and fibrinogen. Paysant J; Vasse M; Soria J; Lenormand B; Pourtau J; Vannier JP; Soria C Br J Haematol; 1998 Jan; 100(1):45-51. PubMed ID: 9450789 [TBL] [Abstract][Full Text] [Related]
37. Urokinase receptor-dependent and -independent p56/59(hck) activation state is a molecular switch between myelomonocytic cell motility and adherence. Chiaradonna F; Fontana L; Iavarone C; Carriero MV; Scholz G; Barone MV; Stoppelli MP EMBO J; 1999 Jun; 18(11):3013-23. PubMed ID: 10357814 [TBL] [Abstract][Full Text] [Related]
38. Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity. Czekay RP; Kuemmel TA; Orlando RA; Farquhar MG Mol Biol Cell; 2001 May; 12(5):1467-79. PubMed ID: 11359936 [TBL] [Abstract][Full Text] [Related]
39. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. Fazioli F; Resnati M; Sidenius N; Higashimoto Y; Appella E; Blasi F EMBO J; 1997 Dec; 16(24):7279-86. PubMed ID: 9405357 [TBL] [Abstract][Full Text] [Related]
40. The urokinase receptor promotes cancer metastasis independently of urokinase-type plasminogen activator in mice. Jo M; Takimoto S; Montel V; Gonias SL Am J Pathol; 2009 Jul; 175(1):190-200. PubMed ID: 19497996 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]